Fidelity Select Pharmaceuticals Portfolio (FPHAX)
34.18
+0.05
(+0.15%)
USD |
Sep 16 2026
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 0.67% | 1.634B | 1.15% | 77.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| 68.47M | 41.09% |
Basic Info
| Investment Strategy | |
| The Fund seeks capital appreciation. Under normal market and economic conditions, the Fund invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types, while using fundamental analysis of factors in selecting investments. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Fidelity Investments |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
34
-299.68M
Peer Group Low
84.66M
Peer Group High
1 Year
% Rank:
7
68.47M
-4.783B
Peer Group Low
170.15M
Peer Group High
3 Months
% Rank:
9
-1.007B
Peer Group Low
200.53M
Peer Group High
3 Years
% Rank:
5
-16.03B
Peer Group Low
314.82M
Peer Group High
6 Months
% Rank:
17
-2.166B
Peer Group Low
414.58M
Peer Group High
5 Years
% Rank:
6
-21.90B
Peer Group Low
372.85M
Peer Group High
YTD
% Rank:
4
-2.817B
Peer Group Low
954.07M
Peer Group High
10 Years
% Rank:
18
-43.07B
Peer Group Low
345.03M
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of September 17, 2026.
Asset Allocation
As of July 31, 2026.
| Type | % Net |
|---|---|
| Cash | 0.17% |
| Stock | 99.58% |
| Bond | 0.26% |
| Convertible | 0.00% |
| Preferred | 0.14% |
| Other | -0.15% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 25.27% | 1143.51 | 0.50% |
| GSK Plc | 8.48% | 50.71 | 0.84% |
| Merck & Co., Inc. | 6.02% | 146.67 | 1.21% |
| Viatris, Inc. | 5.62% | 17.21 | 1.12% |
| AstraZeneca PLC | 4.85% | 165.36 | 1.52% |
| Roche Holding AG | 4.76% | 423.16 | -6.22% |
| Bristol Myers Squibb Co. | 4.69% | 63.34 | -0.41% |
| UCB SA | 4.62% | 248.11 | -0.99% |
| Elanco Animal Health, Inc. | 4.38% | 23.14 | 1.20% |
| Jazz Pharmaceuticals Plc | 4.18% | 245.50 | 0.78% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | 0.65% |
| Administration Fee | -- |
| Maximum Front Load | 0.00% |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | 0.00% |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 0.00 None |
| Minimum Subsequent Investment | 0.00 None |
TTM Distributions
| Type | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Qualified Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Normal
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Qualified
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
LT Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Ordinary Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Non-Qual
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ST Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Interest
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Tax-Exempt
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ROC
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Other
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Total
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
As of August 31, 2026.
Basic Info
| Investment Strategy | |
| The Fund seeks capital appreciation. Under normal market and economic conditions, the Fund invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types, while using fundamental analysis of factors in selecting investments. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Fidelity Investments |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (9-15-26) | 2.86% |
| 30-Day SEC Yield (10-3-23) | 0.00% |
| 7-Day SEC Yield (10-3-23) | 0.00% |
| Number of Holdings | 57 |
| Stock | |
| Weighted Average PE Ratio | 32.00 |
| Weighted Average Price to Sales Ratio | 8.560 |
| Weighted Average Price to Book Ratio | 10.34 |
| Weighted Median ROE | 33.39% |
| Weighted Median ROA | 7.02% |
| Return on Investment (TTM) | 11.05% |
| Earning Yield | 0.0371 |
| LT Debt / Shareholders Equity | 0.9992 |
| Number of Equity Holdings | 53 |
As of July 31, 2026
Growth Metrics
| EPS Growth (1Y) | 43.30% |
| EPS Growth (3Y) | 31.77% |
| EPS Growth (5Y) | 22.84% |
| Sales Growth (1Y) | 18.95% |
| Sales Growth (3Y) | 14.07% |
| Sales Growth (5Y) | 14.84% |
| Sales per Share Growth (1Y) | 95.11% |
| Sales per Share Growth (3Y) | 13.65% |
| Operating Cash Flow - Growth Rate (3Y) | 11.45% |
As of July 31, 2026
Fund Details
| Key Dates | |
| Inception Date | 6/18/2001 |
| Last Annual Report Date | 2/28/2026 |
| Last Prospectus Date | 4/29/2026 |
| Attributes | |
| Index Fund | -- |
| Inverse Fund | No |
| Leveraged Fund | -- |
| Fund of Funds | No |
| Currency Hedged Fund | -- |
| Socially Responsible Fund | No |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:FPHAX", "name") |
| Broad Asset Class: =YCI("M:FPHAX", "broad_asset_class") |
| Broad Category: =YCI("M:FPHAX", "broad_category_group") |
| Prospectus Objective: =YCI("M:FPHAX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |